# Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

> **NCT05773274** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 100 (estimated)

## Conditions studied

- Metastatic Digestive System Neuroendocrine Tumor G1
- Metastatic Digestive System Neuroendocrine Tumor G2
- Unresectable Digestive System Neuroendocrine Tumor G1
- Unresectable Digestive System Neuroendocrine Tumor G2

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Cabozantinib
- **PROCEDURE:** Computed Tomography
- **DRUG:** Everolimus
- **DRUG:** Lutetium Lu 177 Dotatate
- **PROCEDURE:** Magnetic Resonance Imaging
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration
- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT05773274
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-12
- **Primary completion:** 2029-04-30
- **Final completion:** 2029-04-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05773274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05773274, "Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT05773274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*